Endocrinology, Diabetes & Metabolism Case Reports (Nov 2022)

Treating ‘osteoporosis’: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia

  • Mike Lin,
  • Kirtan Ganda

DOI
https://doi.org/10.1530/EDM-22-0300
Journal volume & issue
Vol. 1, no. 1
pp. 1 – 7

Abstract

Read online

We present the case of a 60-year-old female who developed repeated atraumatic stress fractures. She was initially diagnosed with osteoporosis based on her dual-energy X-ray absorptiometry (DXA) scan bone mineral density (BMD) T-scores and started on denosumab therapy. Secondary osteoporosis screen revealed abnormal myeloma screen and low serum phosphate levels. It was thought that the patient had multiple myeloma with associated Fanconi-related tubular dysfunction. However, fibroblast growth factor-23 (FGF-23) levels were grossly elevated, making Fanconi syndrome unlikely. The patient was subsequently diagnosed with two separate conditions, namely cardiac amyloid light-chain (AL) amyloidosis and FGF-23-related hypophosphataemia, likely due to tumour-induced osteomalacia. This case highlights the importance of excluding osteomalacia as a cause of low BMD and checking FGF-23 levels in the workup for hypophosphataemia.